Do analysts recommend GRCE or IMRN?

Grace Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 152.10%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Grace Therapeutics is more favorable than Immuron. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grace Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, GRCE or IMRN?

Immuron has higher revenue and earnings than Grace Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grace Therapeutics N/A N/A -$9.57M -$0.40 N/A Immuron $4.72M 1.83 -$3.38M N/A N/A

Is GRCE or IMRN more profitable?

Immuron's return on equity of 0.00% beat Grace Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Grace Therapeutics N/A -15.58% -14.51% Immuron N/A N/A N/A

Does the media prefer GRCE or IMRN?

In the previous week, Grace Therapeutics had 1 more articles in the media than Immuron. MarketBeat recorded 3 mentions for Grace Therapeutics and 2 mentions for Immuron. Grace Therapeutics' average media sentiment score of 0.60 beat Immuron's score of -0.16 indicating that Grace Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grace Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immuron 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend IMRN or ALGS?

Aligos Therapeutics has a consensus price target of $38.50, indicating a potential upside of 629.17%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aligos Therapeutics is more favorable than Immuron. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aligos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86

Which has better earnings & valuation, IMRN or ALGS?

Immuron has higher revenue and earnings than Aligos Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuron $4.72M 1.83 -$3.38M N/A N/A Aligos Therapeutics $2.19M 14.92 -$24.19M -$8.69 N/A

Does the media refer more to IMRN or ALGS?

In the previous week, Immuron had 1 more articles in the media than Aligos Therapeutics. MarketBeat recorded 2 mentions for Immuron and 1 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.40 beat Immuron's score of -0.16 indicating that Aligos Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuron 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Aligos Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend IMRN or LSTA?

Lisata Therapeutics has a consensus target price of $15.00, indicating a potential upside of 326.14%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Lisata Therapeutics is more favorable than Immuron. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lisata Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has higher earnings and valuation, IMRN or LSTA?

Immuron has higher revenue and earnings than Lisata Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuron $4.72M 1.83 -$3.38M N/A N/A Lisata Therapeutics $170K 188.63 -$16.59M -$1.86 N/A

Is IMRN or LSTA more profitable?

Immuron's return on equity of 0.00% beat Lisata Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Immuron N/A N/A N/A Lisata Therapeutics N/A -103.54% -83.08%

Do analysts rate ATHA or IMRN?

Athira Pharma currently has a consensus price target of $4.00, indicating a potential downside of 51.34%. Given Athira Pharma's higher possible upside, equities analysts plainly believe Athira Pharma is more favorable than Immuron. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athira Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, ATHA or IMRN?

Immuron has higher revenue and earnings than Athira Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athira Pharma N/A N/A -$96.94M -$9.68 N/A Immuron $4.72M 1.83 -$3.38M N/A N/A

Is ATHA or IMRN more profitable?

Immuron's return on equity of 0.00% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Athira Pharma N/A -107.06% -89.89% Immuron N/A N/A N/A

Does the media prefer ATHA or IMRN?

In the previous week, Immuron had 1 more articles in the media than Athira Pharma. MarketBeat recorded 2 mentions for Immuron and 1 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 0.00 beat Immuron's score of -0.16 indicating that Athira Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Athira Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immuron 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer DARE or IMRN?

Dare Bioscience currently has a consensus price target of $10.00, suggesting a potential upside of 360.83%. Given Dare Bioscience's stronger consensus rating and higher possible upside, equities analysts plainly believe Dare Bioscience is more favorable than Immuron. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, DARE or IMRN?

Immuron has higher revenue and earnings than Dare Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dare Bioscience $1.03M 31.56 -$13.40M -$0.95 N/A Immuron $4.72M 1.83 -$3.38M N/A N/A

Is DARE or IMRN more profitable?

Company Net Margins Return on Equity Return on Assets Dare Bioscience N/A N/A -46.22% Immuron N/A N/A N/A

Does the media prefer DARE or IMRN?

In the previous week, Immuron had 1 more articles in the media than Dare Bioscience. MarketBeat recorded 2 mentions for Immuron and 1 mentions for Dare Bioscience. Dare Bioscience's average media sentiment score of 0.00 beat Immuron's score of -0.16 indicating that Dare Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dare Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immuron 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Immuron (IMRN) Competitors

$1.06 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$1.04 -0.02 (-1.42%)

As of 06/18/2026 06:27 PM Eastern

Compare

IMRN vs. GRCE, ALGS, LSTA, ATHA, and DARE

Should you buy Immuron stock or one of its competitors? MarketBeat compares Immuron with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immuron include Grace Therapeutics (GRCE), Aligos Therapeutics (ALGS), Lisata Therapeutics (LSTA), Athira Pharma (ATHA), and Dare Bioscience (DARE). These companies are all part of the "med - biomed/gene" industry.

How does Immuron compare to Grace Therapeutics?

Grace Therapeutics (NASDAQ:GRCE) and Immuron (NASDAQ:IMRN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

Grace Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 152.10%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Grace Therapeutics is more favorable than Immuron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

6.1% of Grace Therapeutics shares are owned by institutional investors. Comparatively, 0.1% of Immuron shares are owned by institutional investors. 11.1% of Grace Therapeutics shares are owned by company insiders. Comparatively, 7.0% of Immuron shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Grace Therapeutics has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market. Comparatively, Immuron has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market.

Immuron has higher revenue and earnings than Grace Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$9.57M	-$0.40	N/A
Immuron	$4.72M	1.83	-$3.38M	N/A	N/A

In the previous week, Grace Therapeutics had 1 more articles in the media than Immuron. MarketBeat recorded 3 mentions for Grace Therapeutics and 2 mentions for Immuron. Grace Therapeutics' average media sentiment score of 0.60 beat Immuron's score of -0.16 indicating that Grace Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grace Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immuron	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immuron's return on equity of 0.00% beat Grace Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-15.58%	-14.51%
Immuron	N/A	N/A	N/A

Summary

Grace Therapeutics beats Immuron on 7 of the 12 factors compared between the two stocks.

How does Immuron compare to Aligos Therapeutics?

Immuron (NASDAQ:IMRN) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

In the previous week, Immuron had 1 more articles in the media than Aligos Therapeutics. MarketBeat recorded 2 mentions for Immuron and 1 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.40 beat Immuron's score of -0.16 indicating that Aligos Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuron	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aligos Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immuron has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Immuron's return on equity of 0.00% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuron	N/A	N/A	N/A
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%

Immuron has higher revenue and earnings than Aligos Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuron	$4.72M	1.83	-$3.38M	N/A	N/A
Aligos Therapeutics	$2.19M	14.92	-$24.19M	-$8.69	N/A

0.1% of Immuron shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 7.0% of Immuron shares are owned by company insiders. Comparatively, 7.8% of Aligos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Aligos Therapeutics has a consensus price target of $38.50, indicating a potential upside of 629.17%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aligos Therapeutics is more favorable than Immuron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Immuron has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.25, meaning that its share price is 125% more volatile than the broader market.

Summary

Aligos Therapeutics beats Immuron on 9 of the 15 factors compared between the two stocks.

How does Immuron compare to Lisata Therapeutics?

Immuron (NASDAQ:IMRN) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Immuron's return on equity of 0.00% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuron	N/A	N/A	N/A
Lisata Therapeutics	N/A	-103.54%	-83.08%

Immuron has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market.

Lisata Therapeutics has a consensus target price of $15.00, indicating a potential upside of 326.14%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Lisata Therapeutics is more favorable than Immuron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Immuron has higher revenue and earnings than Lisata Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuron	$4.72M	1.83	-$3.38M	N/A	N/A
Lisata Therapeutics	$170K	188.63	-$16.59M	-$1.86	N/A

0.1% of Immuron shares are owned by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are owned by institutional investors. 7.0% of Immuron shares are owned by company insiders. Comparatively, 9.6% of Lisata Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Immuron had 2 more articles in the media than Lisata Therapeutics. MarketBeat recorded 2 mentions for Immuron and 0 mentions for Lisata Therapeutics. Lisata Therapeutics' average media sentiment score of 0.60 beat Immuron's score of -0.16 indicating that Lisata Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Immuron	Neutral
Lisata Therapeutics	Positive

Summary

Immuron and Lisata Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Immuron compare to Athira Pharma?

Athira Pharma (NASDAQ:ATHA) and Immuron (NASDAQ:IMRN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

In the previous week, Immuron had 1 more articles in the media than Athira Pharma. MarketBeat recorded 2 mentions for Immuron and 1 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 0.00 beat Immuron's score of -0.16 indicating that Athira Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Athira Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immuron	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immuron's return on equity of 0.00% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-107.06%	-89.89%
Immuron	N/A	N/A	N/A

Immuron has higher revenue and earnings than Athira Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$96.94M	-$9.68	N/A
Immuron	$4.72M	1.83	-$3.38M	N/A	N/A

Athira Pharma has a beta of 2.79, suggesting that its stock price is 179% more volatile than the broader market. Comparatively, Immuron has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market.

Athira Pharma currently has a consensus price target of $4.00, indicating a potential downside of 51.34%. Given Athira Pharma's higher possible upside, equities analysts plainly believe Athira Pharma is more favorable than Immuron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 0.1% of Immuron shares are held by institutional investors. 19.8% of Athira Pharma shares are held by insiders. Comparatively, 7.0% of Immuron shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Athira Pharma and Immuron tied by winning 5 of the 10 factors compared between the two stocks.

How does Immuron compare to Dare Bioscience?

Dare Bioscience (NASDAQ:DARE) and Immuron (NASDAQ:IMRN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	N/A	N/A	-46.22%
Immuron	N/A	N/A	N/A

Dare Bioscience currently has a consensus price target of $10.00, suggesting a potential upside of 360.83%. Given Dare Bioscience's stronger consensus rating and higher possible upside, equities analysts plainly believe Dare Bioscience is more favorable than Immuron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Immuron has higher revenue and earnings than Dare Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	31.56	-$13.40M	-$0.95	N/A
Immuron	$4.72M	1.83	-$3.38M	N/A	N/A

6.7% of Dare Bioscience shares are owned by institutional investors. Comparatively, 0.1% of Immuron shares are owned by institutional investors. 4.1% of Dare Bioscience shares are owned by insiders. Comparatively, 7.0% of Immuron shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Dare Bioscience has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market. Comparatively, Immuron has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

In the previous week, Immuron had 1 more articles in the media than Dare Bioscience. MarketBeat recorded 2 mentions for Immuron and 1 mentions for Dare Bioscience. Dare Bioscience's average media sentiment score of 0.00 beat Immuron's score of -0.16 indicating that Dare Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dare Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immuron	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Dare Bioscience and Immuron tied by winning 6 of the 12 factors compared between the two stocks.

Get Immuron News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMRN vs. The Competition

Export

Metric	Immuron	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.66M	$3.38B	$6.39B	$12.59B
Dividend Yield	N/A	2.31%	2.68%	5.68%
P/E Ratio	N/A	19.73	24.54	24.44
Price / Sales	1.83	318.39	574.74	128.73
Price / Cash	N/A	127.04	44.20	55.21
Price / Book	1.36	8.16	10.83	6.58
Net Income	-$3.38M	$23.89M	$3.57B	$337.17M
7 Day Performance	-10.92%	2.52%	0.71%	0.61%
1 Month Performance	6.00%	5.96%	3.96%	5.02%
1 Year Performance	-39.43%	53.47%	28.49%	35.51%

Immuron Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMRN Immuron	0.1717 of 5 stars	$1.06 flat	N/A	-39.4%	$8.66M	$4.72M	N/A	N/A
GRCE Grace Therapeutics	2.7372 of 5 stars	$2.24 +1.1%	$6.00 +167.4%	-22.5%	$34.72M	N/A	N/A	N/A	News Coverage Upcoming Earnings
ALGS Aligos Therapeutics	3.2975 of 5 stars	$5.31 +6.4%	$38.50 +624.9%	-36.9%	$32.69M	$4.71M	N/A	90
LSTA Lisata Therapeutics	2.3147 of 5 stars	$3.58 +2.6%	$15.00 +319.0%	+40.6%	$32.61M	$170K	N/A	30
ATHA Athira Pharma	0.1586 of 5 stars	$8.22 -4.5%	$4.00 -51.3%	+165.2%	$32.42M	N/A	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMRN) was last updated on 6/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immuron (IMRN) Competitors

IMRN vs. GRCE, ALGS, LSTA, ATHA, and DARE

How does Immuron compare to Grace Therapeutics?

Summary

How does Immuron compare to Aligos Therapeutics?

Summary

How does Immuron compare to Lisata Therapeutics?

Summary

How does Immuron compare to Athira Pharma?

Summary

How does Immuron compare to Dare Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRN vs. The Competition

Immuron Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immuron (IMRN) Competitors

IMRN vs. GRCE, ALGS, LSTA, ATHA, and DARE

How does Immuron compare to Grace Therapeutics?

Do analysts recommend GRCE or IMRN?

Do insiders and institutionals believe in GRCE or IMRN?

Which has more risk and volatility, GRCE or IMRN?

Which has better earnings & valuation, GRCE or IMRN?

Does the media prefer GRCE or IMRN?

Is GRCE or IMRN more profitable?

Summary

How does Immuron compare to Aligos Therapeutics?

Does the media refer more to IMRN or ALGS?

Is IMRN or ALGS more profitable?

Which has better earnings & valuation, IMRN or ALGS?

Do insiders & institutionals believe in IMRN or ALGS?

Do analysts recommend IMRN or ALGS?

Which has more risk & volatility, IMRN or ALGS?

Summary

How does Immuron compare to Lisata Therapeutics?

Is IMRN or LSTA more profitable?

Which has more volatility & risk, IMRN or LSTA?

Do analysts recommend IMRN or LSTA?

Which has higher earnings and valuation, IMRN or LSTA?

Do insiders and institutionals believe in IMRN or LSTA?

Does the media refer more to IMRN or LSTA?

Summary

How does Immuron compare to Athira Pharma?

Does the media prefer ATHA or IMRN?

Is ATHA or IMRN more profitable?

Which has stronger valuation & earnings, ATHA or IMRN?

Which has more risk & volatility, ATHA or IMRN?

Do analysts rate ATHA or IMRN?

Do institutionals & insiders believe in ATHA or IMRN?

Summary

How does Immuron compare to Dare Bioscience?

Is DARE or IMRN more profitable?

Do analysts prefer DARE or IMRN?

Which has better earnings and valuation, DARE or IMRN?

Do insiders and institutionals have more ownership in DARE or IMRN?

Which has more volatility & risk, DARE or IMRN?

Does the media prefer DARE or IMRN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRN vs. The Competition

Immuron Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools